Aerie Pharmaceuticals to Participate in the Raymond James Human Health Innovation Conference

Rhea-AI Summary

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) announced that Vicente Anido, Jr., Ph.D., will present at the Raymond James Human Health Innovation Conference on June 22, 2021, at 1:20 p.m. Eastern Time. The presentation will include an overview and business update of Aerie's operations, particularly its focus on first-in-class therapies for open-angle glaucoma and other ocular diseases. A live webcast of the discussion can be accessed on Aerie's website, with a replay available for 10 business days.

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present in a fireside discussion at the Raymond James Human Health Innovation Conference on Tuesday, June 22, 2021 at 1:20 p.m. Eastern Time. Dr. Anido will provide an Aerie overview and business update.

The fireside discussion will be webcast live and may be accessed by visiting Aerie’s website at http://investors.aeriepharma.com. A replay of the fireside discussion will be available for 10 business days.

About Aerie Pharmaceuticals, Inc.

Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Aerie’s first product, Rhopressa^® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa^®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. More information about Rhopressa^®, including the product label, is available at www.rhopressa.com. Aerie’s second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan^® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa^® and the widely-prescribed PGA (prostaglandin analog) latanoprost, was launched in the United States in May 2019. In clinical trials of Rocklatan^®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. More information about Rocklatan^®, including the product label, is available at www.rocklatan.com. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema. More information is available at www.aeriepharma.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210615005122/en/

FAQ

What is the date and time of Aerie Pharmaceuticals' presentation at the Raymond James Human Health Innovation Conference?

Aerie Pharmaceuticals will present on June 22, 2021, at 1:20 p.m. Eastern Time.

Who will represent Aerie Pharmaceuticals at the conference?

Vicente Anido, Jr., Ph.D., the Chairman and CEO, will represent Aerie Pharmaceuticals.

Where can I access the live webcast of the Aerie Pharmaceuticals presentation?

The live webcast can be accessed on Aerie's website at http://investors.aeriepharma.com.

How long will the replay of Aerie Pharmaceuticals' fireside discussion be available?

The replay will be available for 10 business days after the event.

What are the main areas of focus for Aerie Pharmaceuticals?

Aerie Pharmaceuticals focuses on the development of therapies for open-angle glaucoma, ocular surface diseases, and retinal diseases.